Edition:
United Kingdom

Dr.Reddy's Laboratories Ltd (REDY.NS)

REDY.NS on National Stock Exchange of India

2,565.15INR
14 Jun 2019
Change (% chg)

Rs-23.10 (-0.89%)
Prev Close
Rs2,588.25
Open
Rs2,582.00
Day's High
Rs2,582.00
Day's Low
Rs2,529.00
Volume
689,207
Avg. Vol
903,602
52-wk High
Rs2,964.00
52-wk Low
Rs1,872.95

Latest Key Developments (Source: Significant Developments)

U.S. Appeals Court Rules In Favor Of Lilly In Alimta Vitamin Regimen Patent Lawsuit
Friday, 26 Apr 2019 

April 26 (Reuters) - Eli Lilly and Co ::U.S. COURT OF APPEALS RULES IN FAVOR OF LILLY IN ALIMTA VITAMIN REGIMEN PATENT LAWSUIT.ELI LILLY AND CO - IF PATENT IS ULTIMATELY UPHELD THROUGH ALL REMAINING CHALLENGES, ALIMTA WOULD MAINTAIN U.S. EXCLUSIVITY UNTIL MAY 2022.ELI LILLY - U.S. COURT OF APPEALS DECISION UPHOLDS AN OCTOBER 2017 DECISION BY PATENT TRIAL AND APPEAL BOARD OF U.S. PATENT AND TRADEMARK OFFICE.ELI LILLY AND CO - DR. REDDY'S LABORATORIES AND HOSPIRA HAVE APPEALED DISTRICT COURT'S DECISIONS.ELI LILLY AND CO - HEARING ON THOSE APPEALS IS SCHEDULED FOR JUNE 2019..  Full Article

Dr.Reddy's Laboratories Gets Approval For Clopidogrel In China
Thursday, 25 Apr 2019 

April 25 (Reuters) - Dr.Reddy's Laboratories Ltd ::HAS RECEIVED APPROVAL FOR THE PRODUCT CLOPIDOGREL IN CHINA.SAYS SALES FROM ANTI-BLOOD CLOTTING DRUG WILL NOT BE MATERIAL IN FY2020.  Full Article

Dr.Reddy's Laboratories Says Duvvada Facility Re-inspected By Regulatory Authority Of Germany & Considered To Be Fully Compliant
Friday, 29 Mar 2019 

March 29 (Reuters) - Dr.Reddy's Laboratories Ltd ::FORMULATIONS MANUFACTURING FACILITY IN DUVVADA RE-INSPECTED BY REGULATORY AUTHORITY OF GERMANY & CONSIDERED TO BE FULLY COMPLIANT.  Full Article

Dr.Reddy's Says USFDA Audit Of Shreveport Plant Completed With Zero Observations
Friday, 22 Feb 2019 

Feb 22 (Reuters) - Dr.Reddy's Laboratories Ltd ::AUDIT OF FORMULATIONS SHREVEPORT PLANT, LOUISIANA, USA, BY US FDA, HAS BEEN COMPLETED WITH ZERO OBSERVATIONS.  Full Article

Indivior Launches Generic Version Of Its Suboxone Film
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - Indivior PLC ::INDIVIOR LAUNCHES SUBOXONE FILM AUTHORIZED GENERIC.U.S. AFFILIATE, INDIVIOR INC HAS LAUNCHED AN AUTHORIZED GENERIC VERSION OF SUBOXONE FILM (CIII) IN U.S.AUTHORIZED GENERIC IS BEING MARKETED AND DISTRIBUTED ON INDIVIOR'S BEHALF BY SANDOZ INC.DECISION TO LAUNCH SUBOXONE GENERIC BASED ON MARKET IMPACT EXPECTED FROM ANTICIPATED "AT RISK" LAUNCH OF GENERIC DR. REDDY'S AND/OR ALVOGEN.  Full Article

Indivior Says Court Denied Its Motion To Prevent Sale Of Suboxone Copycats
Tuesday, 12 Feb 2019 

Feb 12 (Reuters) - Indivior PLC ::FEDERAL COURT DENIES MOTION TO STAY.COURT OF APPEALS FOR FEDERAL CIRCUIT DENIES MOTION TO STAY ISSUANCE OF MANDATE.FILED EMERGENCY MOTION TO STAY MANDATE PENDING RESOLUTION OF ITS FORTHCOMING APPLICATION FOR AN ADMINISTRATIVE STAY TO SUPREME COURT OF US.AFTER MANDATE ISSUES, REDDY'S, ALVOGEN WILL NO LONGER BE PREVENTED FROM SELLING OR IMPORTING GENERIC BUPRENORPHINE/NALOXONE SUBLINGUAL FILM.COURT DENIED CO'S MOTION TO STAY ISSUANCE OF MANDATE FOLLOWING CAFC'S RULING VACATING PRELIMINARY INJUNCTION AGAINST DR. REDDY'S.  Full Article

Aquestive Therapeutics Provides Update Regarding Suboxone Sublingual Film Litigation
Tuesday, 5 Feb 2019 

Feb 5 (Reuters) - Aquestive Therapeutics Inc ::AQUESTIVE THERAPEUTICS PROVIDES UPDATE REGARDING SUBOXONE SUBLINGUAL FILM LITIGATION.AQUESTIVE - U.S. COURT DENIED MOTION FOR REHEARING TO REINSTATE PRELIMINARY INJUNCTION AGAINST DR. REDDY'S LABORATORY REGARDING SUBOXONE.AQUESTIVE - DECISION "NOT A JUDGEMENT" IN ONGOING INFRINGEMENT CASES AGAINST DRL AND OTHERS REGARDING POTENTIAL GENERIC PRODUCTS ENTERING U.S. MARKET.  Full Article

U.S. Court Denies Indivior motion relating to preliminary injunction against Dr. Reddy's
Tuesday, 5 Feb 2019 

Feb 5 (Reuters) - Indivior PLC ::INDIVIOR RESPONDS TO CAFC REHEARING DECISION.COURT OF APPEALS FOR FEDERAL CIRCUIT DENIES MOTION FOR REHEARING OR REHEARING EN BANC.TO FILE EMERGENCY MOTION WITH CAFC TO STAY ISSUANCE OF MANDATE PENDING RESOLUTION OF APPEAL OF DECISION FINDING REDDY'S DOES NOT INFRINGE U.S. PATENT.AS A RESULT OF COST INITIATIVES, FY 2019 OPERATING EXPENSE BASE (SG&A AND RESEARCH AND DEVELOPMENT) IS EXPECTED TO BE REDUCED TO $440M TO $460M.CO "FACES MAJOR DISRUPTION" IN IMMEDIATE FUTURE FROM POTENTIAL MATERIAL AND RAPID LOSS OF MARKET SHARE OF SUBOXONE FILM PRODUCT.ASSUMES THAT DRL WILL RESUME LAUNCH OF ITS GENERIC BUPRENORPHINE/NALOXONE SUBLINGUAL FILM PRODUCT IN U.S. ONCE CAFC ISSUES MANDATE.  Full Article

Dr.Reddy's Laboratories Issued Form 483 With 1 Observation By US FDA After Audit Of Co's Plant At Miryalaguda
Monday, 28 Jan 2019 

Jan 28 (Reuters) - Dr.Reddy's Laboratories Ltd ::AUDIT OF CO'S API MANUFACTURING PLANT AT MIRYALAGUDA (NALGONDA DISTRICT), BY US FDA, HAS BEEN COMPLETED ON JAN 28.HAVE BEEN ISSUED A FORM 483 WITH ONE OBSERVATION, WHICH WE ARE ADDRESSING.  Full Article

Dr Reddy's Eyeing $1 Bln Plus Outbound Acquisition In U.S. - ET Now
Tuesday, 22 Jan 2019 

Jan 22 (Reuters) - :DR REDDY'S EYEING $1 BILLION PLUS OUTBOUND ACQUISITION IN U.S. - ET NOW CITING SOURCES.DR REDDY'S EVALUATING BUYOUT OF PRESCRIPTION GENERICS BUSINESS OF PERRIGO- ET NOW CITING SOURCES.  Full Article

Indivior signs deal to sell schizophrenia drug in Canada

May 9 British drugmaker Indivior Plc on Thursday signed a licensing agreement with HLS Therapeutics Inc for the sale of its schizophrenia drug Perseris in Canada.